Self-Disclosure of Breast Cancer Diagnosis by Iranian Women to Friends and Colleagues

Najmabadi, Khadijeh Mirzaii; Atoof, Fatemeh; Latifnejadroudsari, Robab; Shandiz, Fatemeh Homaei; Aledavood, Seyed Amir; Kermani, Ali Taghizadeh; Esmaily, Habibollah

doi:10.7314/apjcp.2014.15.6.2879

Cited by 21 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study in western Iran , recently study [9] and also in eastern Iran [10] show that mean of age in women with breast cancer is around 45 to 50 years, but other recently studies [11,12] , in northwest Iran [13] and in western Iran [14] show that mean of age is around 50 to 70 years. In center of Iran the mean was lower [15] .…”

Section: Discussioncontrasting

confidence: 63%

P53 mutation compared with Ki67 marker in metastasis of breast cancer in western Iran

Payandeh

Sadeghi

Fekri

et al. 2014

JST

View full text Add to dashboard Cite

Objective: To investigate and compare the prognostic value of P53 and Ki67 markers with age and metastasis and survival in patients with breast cancer in Kermanshah, western Iran. Methods: In our study on 116 patients with breast cancer that all of them were women and kind of pathology was invasive ductal carcinoma and patients had Her2 positive. The expression of ki67 marker and p53 genes were determined by immunohistochemistry. Statistical analysis was performed with SPSS version IBM 19 and Disease free survival was calculated using the Kaplan-Meier method and log-rank test. Patients were followed up to 5 years. Results: The age mean of patients was 46.5±10.75.Of 116 patients, 23 patients (19.8%) had breast cancer with metastasis and 93(80.2%) without metastasis. expression of P53 (50%) in 58 patients was positive and 58(50%) was negative. there is a statistically significant relationship between the p53 and metastasis (P<0.05), but no for Ki67. The over expression of p53 protein and Ki67 had no significant relationship with survival rate (P>0.05). Conclusions: The results showed that the Ki67 marker and P53 protein are important factors in the breast cancer patients with emphasis on therapeutic agents.

show abstract

Section: Discussioncontrasting

confidence: 63%

P53 mutation compared with Ki67 marker in metastasis of breast cancer in western Iran

Payandeh

Sadeghi

Fekri

et al. 2014

JST

View full text Add to dashboard Cite

show abstract

“…Attending the exhaustive radiation therapy sessions on a regular basis as well as getting admitted to hospital not only demoralizes patients but also creates plenty of occasions to encounter prejudiced treatment in healthcare settings. It has been reported that Iranian breast cancer patients tend to rely heavily on supports from their own family and 95% of them receive support from siblings, children and friends [24]. In this sense, having more children -as a form of social support-may be protective against stigma, however, meeting their needs may also be overtaxing on their already improvised resources.…”

Section: Discussionmentioning

confidence: 99%

“…Among Iranian urban population, there are negative attitudes around cancer and cancer patients, with most of the respondents in a study reporting their unwillingness to disclose their condition to others if they were ever diagnosed with cancer [23]. In this regard, the working Iranian breast cancer women have shared their contradictory experiences of disease self-disclosure, where about 28% of them were faced with unsatisfactory consequences afterwards, making them change their perception of others and seek distance from people [24]. Moreover, Iranian women who discovered their breast cancer themselves indicated that the very nature of stigmatized cancer of breast as an incurable disease and as the herald of losing femininity made them feel fearful, intimidated and anxious [25].…”

Section: Introductionmentioning

confidence: 99%

Social, Demographical, and Clinical Correlates of Stigma in Iranian Breast Cancer Women

Zamanian¹,

Amini-Tehrani²,

Daryaafzoon³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: This study aimed to assess the severity of disease-related stigma felt by Iranian women with breast cancer as well as to determine the contextual correlates of stigmatization.Methods: This cross-sectional study included 223 breast cancer patients between October-2014 and May-2015, in Tehran, Iran. Eligible patients were asked to provide background data and to complete Stigma Scale for Chronic Illness 8-item (SSCI-8) questionnaire. Binomial logistic regression analysis was employed to identify stigmatized (SSCI-8 > 8) and heavily stigmatized (SSCI-8 >10) groups.Results: A total of 58.3% (n=130) stated that they were stigmatized at least “rarely.” In the multi-variable models in the total sample, living with spouse, Turkic ethnicity, family history of chronic diseases were the significant associations of stigmatization, while no variable was found to be associated with heavily stigmatization. In the sub-sample having the data of spouse’s education (n=185), living with spouse, lower spouse’s education, and family history of chronic diseases were the significant correlates of stigmatization; while, in terms of heavily stigmatization, only the lower spouse’s education was the significant indicator.Conclusions: Stigmatization tails women with breast cancer especially those living with their poorly educated husbands which call for dyadic interventions.

show abstract

“…In addition, estimating life expectancy can play an important role in answering patients. Therefore, finding a way to estimate patients' prognosis is one of the most important fields of research; pathologic and serum biomarkers as the first to explore [10,11]. E-erb B2, i.e.…”

Section: Discussionmentioning

confidence: 99%

Breast Carcinoma; Human Epidermal Growth Factor Receptor-2 (HER-2) and Grading Correlation

Mirmalek

Kani

Mehrabi

et al. 2015

ijtmgh

View full text Add to dashboard Cite

Introduction: Overexpression of Human Epidermal Growth factor Receptor-2 (HER-2) is one of the most important prognostic and predictive factors of breast cancer, observed in 25% -30% of breast carcinoma patients leading to poor prognosis and feasible anti HER-2 antibody drugs. The objective of this study was to evaluate the HER-2 frequency in target population and its correlation with histologic grade as well as tumor pathology, estrogen receptor (ER) and P53 in our patients. Methods: A total of 300 cases (all female) aged 24-80 year, were randomly selected from patients who were admitted in two of the Tehran University of Medical Sciences affiliated centers (Emam Khomeini Cancer Institute and Shariati hospital) over a 2-year period (2013)(2014). Assessment of tumors for HER-2, P53, ER, pathological type and histologic grade was performed. HER-2 over expression defined as three plus (+++) in immunohistochemistry (IHC). Results: The mean age was 49.6±11 years. HER-2 over expression was seen in 34% of the patients. Significant correlations were found between HER-2+, P53+ and high histologic grade and ER (P<0.05). However, there was no significant correlation between HER-2 and pathologic type of tumors in our study. Conclusion: Co-expression of several poor prognostic biomarkers in breast cancer (HER-2 +, P53 +, ER-, high grade) may predict more aggressive phenotype, worse disease and lower overall survival in these patients.

show abstract

Self-Disclosure of Breast Cancer Diagnosis by Iranian Women to Friends and Colleagues

Cited by 21 publications

References 24 publications

P53 mutation compared with Ki67 marker in metastasis of breast cancer in western Iran

P53 mutation compared with Ki67 marker in metastasis of breast cancer in western Iran

Social, Demographical, and Clinical Correlates of Stigma in Iranian Breast Cancer Women

Breast Carcinoma; Human Epidermal Growth Factor Receptor-2 (HER-2) and Grading Correlation

Contact Info

Product

Resources

About